International Journal of Pharmaceutics X
Cure8 research brief
Why This Matters
A formulation that keeps budesonide at the colon surface longer and protects the mucosa could enhance topical treatment for ulcerative colitis and improve mucosal healing compared with standard enemas.
Who Should Pay Attention
Researchers working on topical IBD drug delivery, pharmaceutical scientists, gastroenterology clinicians interested in local therapies for UC, and patients following advances in rectal therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study reports a drug-delivery innovation rather than clinical trial results: the PG oil markedly increases budesonide solubility and transitions to a gel in the colon, aiming to prolong local drug exposure and protect the mucosa.
In mice, rectal BUD-PG improved weight, disease activity indices, colon length, spleen index, reduced pro-inflammatory cytokine staining (IL-6, TNF-α, IL-1β, MCP-1), decreased collagen deposition, and increased markers of barrier integrity (goblet cell replenishment and tight-junction proteins).
These findings support further preclinical development and potential translational studies, but do not establish safety or efficacy in humans.
Keep In Mind
Study results are preclinical (mouse DSS model) and presented as an abstract-level article; this is promising mechanistic work but not clinical evidence. Human safety, tolerability, dosing, and efficacy remain to be tested.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational Journal of Pharmaceutics X
AuthorsTing Ouyang, Yumo Chen, Yiying Jia +6 more
InstitutionWenzhou Medical University
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedAug 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis.
A rectal 5-ASA gel that forms in place and sticks to the mucosa could reduce leakage and improve drug retention, potentially increasing effectiveness and patient comfort for people using topical therapies for ulcerative...
Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations.
Improving colon-targeted delivery of mesalamine could increase drug concentrations at inflamed tissue and reduce release in the stomach and small intestine, which may improve effectiveness and reduce off-target exposure.
in vitro in vivo Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis:andcomparison with non-pH-sensitive and conventional formulations.
A colon-targeted 5-ASA pellet could improve delivery of mesalamine to the diseased colon while reducing release in the stomach; that might increase effectiveness or reduce systemic exposure compared with standard...